Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 18/20 | 0.56 |
| ▸ | CASP7 | P55210 | 2/20 | 0.55 |
| ▸ | CASP9 | P55211 | 2/20 | 0.55 |
| ▸ | CASP6 | P55212 | 2/20 | 0.55 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24213871 | 1.00 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL14646635 | 1.00 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL29384302 | 0.96 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL26071633 | 0.96 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL4466395 | 0.96 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL20257211 | 0.93 | REN (0.55) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL29825423 | 0.93 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL24310885 | 0.92 | REN (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL15012737 | 0.92 | REN (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL24310886 | 0.92 | REN (0.56) | CASP3CASP7CASP9CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3946437-B1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | H LEE MOFFITT CANCER CT & RES (US) | 2025-11-19 | — | — | EP | claimed |
| US-20250163459-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC PHARMACEUTICALS GMBH (DE) | 2025-05-22 | — | — | US | claimed |
| EP-4486872-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC Pharmaceuticals GmbH (DE) | 2025-01-08 | — | — | EP | claimed |
| CN-118995609-A | Neuroblastoma organoid construction formula and method thereof | 北京嘉士腾医学检验实验室有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-118804973-A | Improved cell lines and methods for producing adeno-associated vectors | 塞维克制药有限责任公司 | 2024-10-18 | — | — | CN | claimed |
| WO-2023166026-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC PHARMACEUTICALS GMBH (DE) | 2023-09-07 | — | — | WO | claimed |
| EP-4239063-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC Pharmaceuticals GmbH (DE) | 2023-09-06 | — | — | EP | claimed |
| CN-116392595-A | Application of scorch signal path inhibitor in preparation of orthodontic tooth root absorption medicine | 四川大学 | 2023-07-07 | — | — | CN | claimed |
| US-20230032934-A1 | METHOD OF PRODUCING TUMOR-REACTIVE T CELL COMPOSITION USING MODULATORY AGENTS | MYST THERAPEUTICS, LLC (US) | 2023-02-02 | — | — | US | claimed |
| EP-4110799-A1 | METHODS FOR EX VIVO ENRICHMENT AND EXPANSION OF TUMOR REACTIVE T CELLS AND RELATED COMPOSITIONS THEREOF | Myst Therapeutics, LLC (US) | 2023-01-04 | — | — | EP | claimed |
| CN-115427438-A | Methods for ex vivo enrichment and expansion of tumor-reactive T cells and compositions related thereto | 迈斯特治疗公司 | 2022-12-02 | — | — | CN | claimed |
| EP-4065229-A1 | METHOD OF PRODUCING TUMOR-REACTIVE T CELL COMPOSITION USING MODULATORY AGENTS | Myst Therapeutics, LLC (US) | 2022-10-05 | — | — | EP | claimed |
| CN-115023270-A | Methods of generating tumor-reactive T cell compositions using modulators | 迈斯特治疗公司 | 2022-09-06 | — | — | CN | claimed |
| US-20220177841-A1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | MYST THERAPEUTICS LLC (US) | 2022-06-09 | — | — | US | claimed |
| CN-106796219-B | Stabilization of whole blood samples | 通用医疗公司 | 2022-05-27 | — | — | CN | claimed |
| CN-114269370-A | Methods of ex vivo production of T cell therapeutics and related compositions and methods | 迈斯特治疗公司 | 2022-04-01 | — | — | CN | claimed |
| EP-3946437-A1 | EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS | Myst Therapeutics, LLC (US) | 2022-02-09 | — | — | EP | claimed |
| US-20210007348-A1 | STABILIZATION OF WHOLE BLOOD SAMPLES | THE GENERAL HOSPITAL CORPORATION | 2021-01-14 | — | — | US | claimed |
| EP-3698628-A1 | STABILIZATION OF WHOLE BLOOD SAMPLES | The General Hospital Corporation (US) | 2020-08-26 | — | — | EP | claimed |
| US-10750739-B2 | Stabilization of whole blood samples | THE GENERAL HOSPITAL CORPORATION (US) | 2020-08-25 | — | — | US | claimed |